Who’s Guarding What?

May 2006, the Gardasil vaccine was approved for use in the United States in a bid to stop the spread of four strains of the human papillomavirus (HPV) which can lead to cervical cancer. Since then, media outlets have highly praised the vaccine and it has been marketed and promoted all over the world, whilst the vaccines adverse side effects have been pushed aside, leaving those with negative reactions to suffer.

Did you know that there are over 100 strains of the HPV virus, which is a sexually transmitted disease?  How can a vaccine be highly praised when 96% of the strains continue to pose a risk – is the vaccine worth it?

Longitudinal studies have not been completed in regards to this relatively ‘new’ vaccine and this may lead to major concerns and ramifications if it’s continued to be injected into women. For several decades, numerous case reports and studies documenting neurological and autoimmune adverse reactions following the use of various vaccinations have been conducted but not for the HPV vaccines.

Two researchers funded by the Children’s Medical Safety Research Institute, Christopher Shaw and Lucija Tomljenovic, found two young women who suffered from fatal cerebral vasculitis-type symptoms, following a vaccination with the HPV vaccine Gardasil. Cerebral vasculitis is a serious disease, typically resulting in deadly outcomes if it is left undiagnosed and untreated. In some cases vaccination may be the triggering factor of fatal autoimmune/neurological events.

Shaw and Tomljenovic discovered an interesting correlation that involved certain antibodies and antigens found in Gardasil. They discovered that these antibodies and antigens were stained in the brain tissue of two women. This link might have explained the death of these individuals because the autoimmune vasculitis may have potentially been triggered by the cross-reactive HPV-16L1 antibodies found in Gardasil.

The case study showed signs of the two women having antibodies and antigens adhered to their post-mortem brain tissue. Some of the Gardasil antibodies were binding to the wall of the cerebral blood vessels, causing the body to abnormally activate an immune response so as to attack the antibodies; however, the response triggered the immune attack towards self-tissue, resulting in a fatal outcome.

Shaw and Tomljenovic concluded that HPV vaccines containing HPV-16L1 antigens, pose an inherent risk for triggering potentially fatal autoimmune vasculopathies. The HPV vaccine Gardasil continues to be used on many young women around the world, even though its adverse effects are beginning to surface.